entertainment -WSS

entertainment

author：Wikipedia 2025-09-29 16:33:18 - browse：18

Marc Tessier Lavigne (center) retracted two Science papers on the day his resignation as Stanford president takes effect. Mattarella in San Francisco

After an expansive investigation found manipulated data and other issues with papers co-authored by Stanford’s now ex-president Marc Tessier-Lavigne, the prominent neuroscientist on Thursday retracted two studies published in the journal Science in 2001 — over the objection of a former postdoctoral researcher who played a leading role in both projects.

The retractions come the same day that Tessier-Lavigne’s resignation as Stanford president takes effect. His departure was prompted by a 95-page report released by a special committee of the university’s Board of Trustees, which recruited outside scientists and a former federal judge to investigate a dozen papers Tessier-Lavigne co-authored between 1999 and 2009, years before becoming the university’s leader.

The panel concluded that he did not personally engage in scientific misconduct, but it uncovered manipulated data in some studies Tessier-Lavigne had supervised and found that he took insufficient steps to “decisively and forthrightly” correct these studies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： UnitedHealth, Optum discontinue NaviHealth name

entertainment

hotspot

WSS

Results on Novartis prostate cancer therapy could expand its use

Readout LOUD podcast: Live from the 2023 STAT Summit

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

Why a market frenzy over new weight loss drugs defies logic

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

leisure time

entertainment

knowledge

The high cost of giving birth even with insurance

STAT Summit: Meghan O’Rourke on making chronic illness visible

Alkermes shareholders re

ADCs take center stage as promising cancer treatments

United colonoscopy coverage change 'may cost lives,' doctors say

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Guidelines to prevent youth baseball injuries need more muscle

Even great ERs can’t make up for American health disparities

Sports medicine is finally prioritizing gender equality

FDA drug safety: Singulair case shows systemic surveillance flaws

leisure time

Roivant's CEO is a star, but biotech's black hole persists

Merck, Daiichi strike cancer drug pact worth up to $22 billion

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

A $475,000 price tag for a new cancer drug: crazy or meh?

Vertex non

Quicker fix for pulse oximeters urged during FDA public meeting

entertainment

hotspot

focus

hotspot